W
Wonsuk Chang
Researcher at Merck & Co.
Publications - 45
Citations - 2478
Wonsuk Chang is an academic researcher from Merck & Co.. The author has contributed to research in topics: Nucleoside & Prodrug. The author has an hindex of 21, co-authored 45 publications receiving 2163 citations. Previous affiliations of Wonsuk Chang include Seoul National University & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
Michael J. Sofia,Donghui Bao,Wonsuk Chang,Jinfa Du,Dhanapalan Nagarathnam,Rachakonda Suguna,P. Ganapati Reddy,Bruce S. Ross,Peiyuan Wang,Hai-Ren Zhang,Shalini Bansal,Christine Espiritu,Meg Keilman,Angela M. Lam,Holly M. Micolochick Steuer,Congrong Niu,Michael J. Otto,Phillip A. Furman +17 more
TL;DR: Phosphoramidate prodrugs of the 5'-phosphate derivative of the β-d- 2'-deoxy-2'-α-fluoro-2-β-C-methyluridine nucleoside showed significant potency in the HCV subgenomic replicon assay and produced high levels of triphosphates 6 in primary hepatocytes and in the livers of rats, dogs, and monkeys when administered in vivo.
Journal ArticleDOI
Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977
Eisuke Murakami,Tatiana Tolstykh,Haiying Bao,Congrong Niu,Holly M. Micolochick Steuer,Donghui Bao,Wonsuk Chang,Christine Espiritu,Shalini Bansal,Angela M. Lam,Michael J. Otto,Michael J. Sofia,Phillip A. Furman +12 more
TL;DR: A phosphoramidate prodrug of 2′-deoxy-2′-α-fluoro-β-C-methyluridine-5′-monophosphate, PSI-7851, demonstrates potent anti-hepatitis C virus (HCV) activity both in vitro and in vivo.
Journal ArticleDOI
Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase
Journal ArticleDOI
An orally available non-nucleotide STING agonist with antitumor activity
Bo-Sheng Pan,Samanthi A. Perera,Jennifer Piesvaux,Jeremy Presland,Gottfried K. Schroeder,Jared N. Cumming,B. Wesley Trotter,Michael D. Altman,Alexei V. Buevich,Brandon Cash,Saso Cemerski,Wonsuk Chang,Yiping Chen,Peter J. Dandliker,Guo Feng,Andrew M. Haidle,Timothy J. Henderson,James P. Jewell,Ilona Kariv,Ian Knemeyer,Johnny E. Kopinja,Brian M. Lacey,Jason Laskey,Charles A. Lesburg,Rui Liang,Brian Long,Min Lu,Yanhong Ma,Ellen C. Minnihan,Greg O’Donnell,Ryan D. Otte,Laura Price,Larissa Rakhilina,Berengere Sauvagnat,Sharad K. Sharma,Sriram Tyagarajan,Hyun Chong Woo,Daniel F. Wyss,Serena Xu,David Jonathan Bennett,George H. Addona +40 more
TL;DR: A previously unknown compound (MSA-2) that exhibits “closed” STING conformation and antitumor immunity is identified and identified in a phenotypic screen for chemical inducers of interferon-β secretion.
Patent
Cyclic di-nucleotide compounds as sting agonists
Michael D. Altman,Brian M. Andresen,Wonsuk Chang,Matthew Lloyd Childers,Jared N. Cumming,Andrew M. Haidle,Timothy J. Henderson,James P. Jewell,Rui Liang,Jongwon Lim,Hong Liu,Min Lu,Alan B. Northrup,Ryan D. Otte,Tony Siu,Benjamin Wesley Trotter,Quang T. Truong,Shawn P. Walsh,Kake Zhao +18 more
TL;DR: In this article, a class of polycyclic compounds of general formula (II), of general form (II'), or of general condition (II) was defined, which may be useful as inductors of type I interferon production, specifically as STING active agents.